Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REDEX: Phase 1 Study of Reducing Prophylactic Dexamethasone Around Docetaxel Infusion
NCT02776436Phase 1Completed
- Sponsor
- Leiden University Medical Center
- Start
- Jan 2016
- Primary completion
- Nov 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of dexamethasone in Hypersensitivity and edema (2 arms), sponsored by Leiden University Medical Center. Primary endpoint: Optimal dose/recommended dose (RD) of pre-medication dexamethasone around docetaxel infusion at 30 weeks. Started Jan 2016; status: completed.
02
Drugs
dexamethasone
03
Conditions
Hypersensitivityedema
Beyond the preview
Go deeper on NCT02776436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02776436.